Status:
RECRUITING
Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence
Lead Sponsor:
Nicole Baca
Conditions:
Neurofibromatosis Type 1
Eligibility:
All Genders
5-17 years
Phase:
NA
Brief Summary
This is a single arm pilot trial of a novel whole-body Magnetic Resonance Imaging paired with artificial intelligence intervention, to evaluate feasibility defined as scan-rescan reliability, and to e...
Eligibility Criteria
Inclusion
- Between the ages of 5 and \<18 years at the start of study. If subject will turn 18 during the study, they will be allowed to enroll.
- Clinically or molecularly confirmed diagnosis of NF-1. Subjects with mosaic/segmental NF-1 also qualify for the study.
Exclusion
- Requiring sedation for imaging.
- Implants and/or Devices: Mechanical, magnetic or electrical activated implants; Ferromagnetic implants and foreign bodies
- Claustrophobia, problems being in enclosed spaces, or inability to lie facing upwards.
- Allergy to animal dander or animal-instigated asthma.
Key Trial Info
Start Date :
July 8 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2027
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT04763109
Start Date
July 8 2022
End Date
May 1 2027
Last Update
September 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cedars Sinai Medical Center
Los Angeles, California, United States, 90048